var data={"title":"Insulin regular: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Insulin regular: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/159801?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=insulin-regular-patient-drug-information\" class=\"drug drug_patient\">see &quot;Insulin regular: Patient drug information \t&quot;</a> and <a href=\"topic.htm?path=insulin-regular-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Insulin regular: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50707944\" class=\"block spa drugH1Div\"><span class=\"drugH1\">Special Alerts</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Insulin Pen Safety Alert</span>\n      <span class=\"collapsible-date\">October 2017</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:0em;\">The Institute for Safe Medication Practices (ISMP) National Medication Errors Reporting Program (MERP) has issued a safety alert regarding reports of patients incorrectly using insulin pens at home, resulting in severe cases of hyperglycemia. Patients were not removing the inner cover of a standard insulin pen needle prior to attempting to administer the insulin, and thus were not receiving insulin doses.</p>\n        <p style=\"text-indent:0em;\">Health care professionals should instruct patients on the proper use of insulin pens and require patient demonstration to verify understanding. They should also verify which pen needles patients will be using at home, either standard pens or pens with automatic needle retraction devices, and tailor instruction accordingly.</p>\n        <p style=\"text-indent:0em;\">More information can be found at http://www.ismp.org/NAN/files/NAN-20171012.pdf.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2105104\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>HumuLIN R U-500 (CONCENTRATED);</li>\n      <li>HumuLIN R U-500 KwikPen;</li>\n      <li>HumuLIN R [OTC];</li>\n      <li>NovoLIN R ReliOn [OTC];</li>\n      <li>NovoLIN R [OTC]</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2104962\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Entuzity KwikPen;</li>\n      <li>Humulin R;</li>\n      <li>Novolin ge Toronto</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2104964\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Insulin, Short-Acting</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2104988\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Diabetes mellitus: </b> SubQ: <b>Note:</b> Insulin requirements vary dramatically between patients and therapy requires dosage adjustments with careful medical supervision. Specific formulations may require distinct administration procedures; please see individual agents.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>\n        <i>Diabetes mellitus, type 1:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>General insulin dosing (off-label): </b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Note:</b> Multiple daily doses or continuous subcutaneous infusions guided by blood glucose monitoring are the standard of diabetes care. Combinations of insulin formulations are commonly used. The daily doses presented below are expressed as the <b>total units/kg/day of all insulin formulations combined</b>. In most type 1 patients, the use of a rapid-acting insulin analog is preferred over regular insulin to reduce hypoglycemia risk (ADA 2017f).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>\n        <i>Initial total insulin dose:</i></b> 0.2 to 0.6 units/kg/day in divided doses. Conservative initial doses of 0.2 to 0.4 units/kg/day are often recommended to avoid the potential for hypoglycemia. A rapid-acting insulin may be the only insulin formulation used initially.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>\n        <i>Usual maintenance range:</i></b> 0.5 to 1 units/kg/day in divided doses. An estimate of anticipated needs may be based on body weight and/or activity factors as follows:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Nonobese: 0.4 to 0.6 units/kg/day</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Obese: 0.8 to 1.2 units/kg/day</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>\n        <i>Division of daily insulin requirement (&ldquo;conventional therapy&rdquo;):</i></b> Generally, 50% to 75% of the total daily dose (TDD) is given as an intermediate- or long-acting form of insulin (in 1 to 2 daily injections). The remaining portion of the TDD is then divided and administered before or at mealtimes (depending on the formulation) as a rapid-acting (eg, lispro, aspart, glulisine) or short-acting (regular) form of insulin. Some patients may benefit from the use of CSII which delivers rapid-acting insulin as a continuous infusion throughout the day and as boluses at mealtimes via an external pump device.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>\n        <i>Division of daily insulin requirement (&ldquo;intensive therapy&rdquo;):</i></b> Basal insulin delivery with 1 or 2 doses of intermediate- or long-acting insulin formulations superimposed with doses of short-acting (regular) insulin or rapid-acting insulin (eg, lispro, aspart, glulisine) formulations 3 or more times daily.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Dosage adjustment:</i> Dosage must be titrated to achieve glucose control and avoid hypoglycemia. Since combinations of agents are frequently used, dosage adjustment must address the individual component of the insulin regimen which most directly influences the blood glucose value in question, based on the known onset and duration of the insulin component. Treatment and monitoring regimens must be individualized.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Continuous SubQ insulin infusion (insulin pump):</i> Using an appropriate rapid-acting insulin formulation, consists of a combination of a &quot;basal&quot; continuous insulin infusion rate with preprogrammed, premeal bolus doses that are patient controlled. When converting from multiple daily SubQ doses of maintenance insulin, it is advisable to reduce the basal rate to less than the equivalent of the total daily units of the longer acting insulin (eg, NPH); divide the total number of units by 24 to get the basal rate in units/hour. Do not include the total units of regular insulin or other rapid-acting insulin formulations in this calculation. The same premeal regular insulin dosage may be used.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>\n        <i>Diabetes mellitus, type 2:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>General considerations for insulin use in type 2 diabetes (off-label):</b></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Timing of </i>\n      <i>initiation:</i> Dual therapy (metformin + a second antihyperglycemic agent) and then triple therapy (metformin + two antihyperglycemic agents) is recommended in patients who fail to achieve glycemic goals after ~3 months with lifestyle intervention and metformin monotherapy or dual therapy, respectively (unless contraindications to metformin exist). Preference is not given for which agent(s) should be added to metformin (drug choice should be individualized based on patient characteristics). If HbA<sub>1c</sub> target not achieved after ~3 months of triple therapy, consider initiating basal insulin (usually with metformin +/- other noninsulin agent) or if patient already receiving an optimally titrated <b>basal</b> insulin (ie, a long-acting insulin such as glargine, degludec, or detemir) as part of their regimen, consider combination injectable therapy (ADA 2017f).</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Combination injectable therapy:</i> If HbA<sub>1c</sub> target has not been met with <b>basal </b>insulin (ie, long-acting insulin such as glargine, degludec or detemir) (usually combined with metformin +/- other noninsulin agent), despite titrating <b>basal</b> insulin to provide acceptable fasting blood glucose concentrations, combination injectable therapy should be considered. Options include: adding a rapid-acting insulin (eg, lispro, aspart, glulisine) prior to largest meal <b>or</b> adding a GLP-1 receptor agonist <b>or</b> changing from <b>basal </b>insulin to a twice daily premixed insulin. If HbA<sub>1c </sub>still not adequately controlled, consider advancing from one rapid-acting insulin prior to largest meal to &lsquo;basal-bolus&rsquo; regimen (ie, rapid-acting insulin administered before &ge;2 meals) <b>or</b> consider advancing from a twice daily premixed insulin to a three times daily premixed insulin (ADA 2017f).</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Patients with </i>\n      <i>elevated HbA<sub>1C</sub> at therapy initiation:</i> If HbA<sub>1c</sub> is &ge;9% at initiation of therapy, dual therapy (metformin + a second antihyperglycemic agent) should be considered. If HbA<sub>1c</sub> &ge;10%, blood glucose is &ge;300 mg/dL or if patient is symptomatic (eg, polyuria, polydipsia), insulin therapy (with or without additional agents) should be considered (ADA 2017f).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Cadaveric organ recovery (hormonal resuscitation) (off-label use):</b> IV: Continuous infusion of 1 unit/hour (minimum dose) to maintain blood glucose of 120 to 180 mg/dL <b>or</b> 20 units as a bolus dose (after an IV bolus of dextrose 25 g) administered to the brain-dead donor who is hemodynamically unstable requiring significant vasopressor support; give concomitantly with levothyroxine or liothyronine (preferred), vasopressin, and methylprednisolone (Rosendale 2003a; Rosendale 2003b; Rosengard 2002; Salim 2007; Zaroff 2002).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Diabetic ketoacidosis (DKA) (off-label use):</b> Only IV regular insulin should be used for severe DKA (Kitabchi 2009). Treatment should continue until reversal of acid-base derangement/ketonemia. Serum glucose is not a direct indicator of these abnormalities, and may decrease more rapidly than correction of the metabolic abnormalities. Also, refer to institution-specific protocols where appropriate.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults &lt;20 years (Kitabchi 2004):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IV infusion: 0.1 units/kg/hour</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Adjustment: </i> If serum glucose does not fall by 50 mg/dL in the first hour, check hydration status; if acceptable, double insulin dose hourly until glucose levels fall at rate of 50 to 75 mg/dL per hour. Once serum glucose reaches 250 mg/dL, decrease dose to 0.05 to 0.1 units/kg/hour; dextrose-containing IV fluids should be administered to maintain serum glucose between 150 to 250 mg/dL until the acidosis clears. After resolution of DKA, supplement IV insulin with SubQ insulin as needed until the patient is able to eat and transition fully to a SubQ insulin regimen. An overlap of ~1 to 2 hours between discontinuation of IV insulin and administration of SubQ insulin is recommended to ensure adequate plasma insulin levels.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">SubQ, IM (<b>Note:</b> Only use the SubQ and IM route if IV infusion access is unavailable): 0.1 to 0.3 units/kg SubQ bolus, followed by 0.1 units/kg given every hour SubQ or IM or 0.15 to 0.2 units/kg every 2 hours SubQ; continue until acidosis clears, then decrease to 0.05 units/kg given every hour until SubQ replacement dosing can be initiated (Kitabchi 2004; Wolfsdorf 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults &ge;20 years (Kitabchi 2009):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IV:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Bolus:</i> 0.1 units/kg (optional)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Infusion:</i> 0.1 to 0.14 units/kg/hour. <b>Note:</b> If no IV bolus was administered, patients should receive a continuous infusion of 0.14 units/kg/hour; lower doses may not achieve adequate insulin concentrations to suppress hepatic ketone body production.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Adjustment:</i> If serum glucose does not fall by at least 10% in the first hour, give an IV bolus of 0.14 units/kg and continue previous regimen. In addition, if serum glucose does not fall by 50 to 70 mg/dL in the first hour, the insulin infusion dose should be increased hourly until a steady glucose decline is achieved Once serum glucose reaches 200 mg/dL, decrease infusion dose to 0.02 to 0.05 units/kg/hour or switch to SubQ rapid-acting insulin (eg, aspart, lispro) at 0.1 units/kg every 2 hours; dextrose-containing IV fluids should be administered to maintain serum glucose between 150 to 250 mg/dL until the acidosis clears. After resolution of DKA, supplement IV insulin with SubQ insulin as needed until the patient is able to eat and transition fully to a SubQ insulin regimen. An overlap of ~1 to 2 hours between discontinuation of IV insulin and administration of SubQ insulin is recommended to ensure adequate plasma insulin levels.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">SubQ, IM: The following dosing regimen from the 2004 ADA position statement recommends regular insulin (Kitabchi 2004):</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Bolus:</i> 0.4 units/kg; <b>Note:</b> Give half of the dose (0.2 units/kg) as an IV bolus and half of the dose (0.2 units/kg) as SubQ or IM</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Intermittent:</i> 0.1 units/kg given every hour SubQ or IM</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Adjustment:</i> If serum glucose does not fall by 50 to 70 mg/dL in the first hour, administer 10 units hourly by IV bolus until glucose levels fall at a rate of 50 to 70 mg/dL per hour. Once serum glucose reaches 250 mg/dL, decrease dose to 5 to 10 units SubQ every 2 hours; dextrose-containing IV fluids should be administered to maintain serum glucose between 150 to 250 mg/dL until the acidosis clears.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Hyperglycemia, critically ill (off-label use):</b> Adults: IV continuous infusion: Insulin therapy should be implemented when blood glucose &ge;150 mg/dL with a goal to maintain blood glucose &lt;150 mg/dL (with values absolutely &lt;180 mg/dL) using a protocol that achieves a low rate of hypoglycemia (ie, &le;70 mg/dL). Alternatively, other rapid acting insulin analogues (eg, insulin aspart or insulin glulisine) may also be used as a continuous infusion to maintain glycemic control (in place of regular insulin). Before discontinuation, stable ICU patients should be transitioned to a protocol-driven basal/bolus insulin regimen, based on insulin infusion history and carbohydrate intake, to avoid loss of glycemic control. Subcutaneous insulin therapy may be considered for selected clinically stable ICU patients (SCCM [Jacobi 2012]). <b>Note:</b> The Surviving Sepsis Campaign guidelines recommend initiating insulin dosing in patients with severe sepsis when 2 consecutive blood glucose concentrations are &gt;180 mg/dL and to target an upper blood glucose &le;180 mg/dL (Rhodes 2017).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Hyperkalemia, moderate-to-severe (off-label use):</b> IV: 10 units regular insulin mixed with 25 g dextrose (50 mL D<sub>50</sub>W) given over 15 to 30 minutes (ACLS 2010); alternatively, 50 mL D<sub>50</sub>W over 5 minutes followed by 10 units regular insulin IV push over seconds may be administered in the setting of imminent cardiac arrest. In patients with ongoing cardiac arrest (eg, PEA with presumed hyperkalemia), administration of D<sub>50</sub>W over &lt;5 minutes is routine. Effects on potassium are temporary. As appropriate, consider methods of enhancing potassium removal/excretion.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Hyperosmolar hyperglycemic state (HHS) (off-label use):</b> Only regular injectable insulin should be used. Infusion should continue until reversal of mental status changes and hyperosmolality. Serum glucose is not a direct indicator of these abnormalities, and may decrease more rapidly than correction of the metabolic abnormalities. Also, refer to institution-specific protocols where appropriate.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults &lt;20 years (Kitabchi 2004):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IV:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Infusion:</i> 0.1 units/kg/hour</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Adjustment:</i> If serum glucose does not fall by 50 mg/dL in the first hour, check hydration status; if acceptable, double insulin dose hourly until glucose levels fall at rate of 50 to 75 mg/dL per hour. Once serum glucose reaches 300 mg/dL, decrease dose to 0.05 to 0.1 units/kg/hour; dextrose-containing IV fluids should be administered to maintain serum glucose between 250 to 300 mg/dL until hyperosmolality clears and mental status returns to normal. After resolution of HHS, supplement IV insulin with SubQ insulin as needed until the patient is able to eat and transition fully to a SubQ insulin regimen. An overlap of ~1 to 2 hours between discontinuation of IV insulin and administration of SubQ insulin is recommended to ensure adequate plasma insulin levels.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">SubQ, IM (<b>Note:</b> Only use the SubQ and IM route if IV infusion access is unavailable): 0.1 to 0.3 units/kg SubQ bolus, followed by 0.1 units/kg given every hour SubQ or IM or 0.15 to 0.2 units/kg every 2 hours SubQ; continue until resolution of hyperosmolality, then decrease to 0.05 units/kg given every hour until SubQ replacement dosing can be initiated (Kitabchi 2004; Wolfsdorf 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults &ge;20 years (Kitabchi 2009):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IV:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Bolus:</i> 0.1 units/kg bolus (optional)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Infusion:</i> 0.1 to 0.14 units/kg/hour. <b>Note:</b> If no IV bolus was administered, patients should receive a continuous infusion of 0.14 units/kg/hour.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Adjustment:</i> If serum glucose does not fall by at least 10% in the first hour, give an IV bolus of 0.14 units/kg and continue previous regimen. In addition, if serum glucose does not fall by 50 to 70 mg/dL in the first hour, the insulin infusion dose should be increased hourly until a steady glucose decline is achieved. Once serum glucose reaches 300 mg/dL, decrease dose to 0.02 to 0.05 units/kg/hour; dextrose-containing IV fluids should be administered to maintain serum glucose between 200 to 300 mg/dL until the patient is mentally alert. After resolution of HHS, supplement IV insulin with SubQ insulin as needed until the patient is able to eat and transition fully to a SubQ insulin regimen. An overlap of ~1 to 2 hours between discontinuation of IV insulin and administration of SubQ insulin is recommended to ensure adequate plasma insulin levels.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2104987\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=insulin-regular-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Insulin regular: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">The general objective of insulin replacement therapy is to approximate the physiologic pattern of insulin secretion. This requires a basal level of insulin throughout the day, supplemented by additional insulin at mealtimes. Since combinations using different types of insulins are frequently used, dosage adjustment must address the individual component of the insulin regimen which most directly influences the blood glucose value in question, based on the known onset and duration of the insulin component. The frequency of doses and monitoring must be individualized in consideration of the patient's ability to manage therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Diabetes mellitus, type 1:</b> SubQ: Infants (Limited data available), Children, and Adolescents: <b>Note:</b> Insulin regimens should be individualized to achieve glycemic goals without causing hypoglycemia. Multiple daily doses or continuous subcutaneous infusion guided by blood glucose monitoring are the standard of diabetes care. The daily doses presented are expressed as the total units/kg/day <b>of all insulin formulations combined</b>.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>General insulin dosing (off-label): </b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Initial dose:</i> SubQ: 0.2 to 0.6 units/kg/day in divided doses. Conservative initial doses of 0.2 to 0.4 units/kg/day are often recommended to avoid the potential for hypoglycemia.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Usual maintenance range:</i> 0.5 to 1 unit/kg/day in divided doses; doses must be individualized; however an estimate can be determined based on phase of diabetes and level of maturity (ISPAD [Danne 2014])</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Partial remission phase (Honeymoon phase): &lt;0.5 units/kg/day</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Prepubertal children (not in partial remission): 0.7 to 1 units/kg/day</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Pubescent Children and Adolescents: During puberty, requirements may substantially increase to &gt;1.2 unit/kg/day and in some cases up to 2 units/kg/day</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Division of daily insulin requirement (&quot;conventional therapy&quot;):</i> Generally, 50% to 75% of the daily insulin dose is given as an intermediate- or long-acting form of insulin (in 1 to 2 daily injections). The remaining portion of the 24-hour insulin requirement is divided and administered as either regular insulin or a rapid-acting form of insulin at the same time before breakfast and dinner.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Division of daily insulin requirement (&quot;intensive therapy&quot;):</i> Basal insulin delivery with 1 or 2 doses of intermediate- or long-acting insulin formulations superimposed with doses of rapid- or very rapid-acting insulin formulations 3 or more times daily.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Dosage adjustment:</i> Dosage must be titrated to achieve glucose control and avoid hypoglycemia. Since combinations of agents are frequently used, dosage adjustment must address the individual component of the insulin regimen which most directly influences the blood glucose value in question, based on the known onset and duration of the insulin component.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Continuous SubQ insulin infusion (insulin pump):</i> Using an appropriate rapid-acting insulin formulation, consists of a combination of a &quot;basal&quot; continuous insulin infusion rate with preprogrammed, premeal bolus doses which are patient controlled. When converting from multiple daily SubQ doses of maintenance insulin, it is advisable to reduce the basal rate to less than the equivalent of the total daily units of longer acting insulin (eg, NPH). Divide the total number of units by 24 to get the basal rate in units/hour. Do not include the total units of regular insulin or other rapid-acting insulin formulations in this calculation. The same premeal regular insulin dosage may be used.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Diabetes mellitus, type 2:</b> Children &ge;10 years and Adolescents: SubQ: The goal of therapy is to achieve an HbA<sub>1c</sub> &lt;6.5% as quickly as possible using the safe titration of medications. Initial therapy in metabolically unstable patients (eg, plasma glucose &ge; 250 mg/dL, HbA<sub>1c</sub> &gt;9% and symptoms excluding acidosis) may include once daily intermediate-acting insulin or basal insulin in combination with lifestyle changes and metformin. In patients who fail to achieve glycemic goals with metformin and basal insulin, may consider initiating prandial insulin (regular insulin or rapid acting insulin) and titrate to achieve goals. Once initial goal reached, insulin should be slowly tapered and the patient transitioned to lowest effective doses or metformin monotherapy if able (AAP [Copeland 2013]; ISPAD [Zeitler 2014]). <b>Note:</b> Patients who are ketotic or present with ketoacidosis require aggressive management as indicated.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Diabetic ketoacidosis (DKA) (off-label use):</b> Infants, Children, and Adolescents: <b>Note:</b> Only IV regular insulin should be used for treatment of DKA; the rare exception where the use of SubQ rapid-acting insulin analogs (eg, aspart, lispro) may be appropriate is for patients with uncomplicated DKA in whom peripheral circulation is adequate and continuous IV regular insulin administration is not possible. Treatment should continue until resolution of acid-base abnormalities (eg, pH &gt;7.3, serum HCO3 &gt;15 mEq/L, and/or closure of anion gap); serum glucose is not a direct indicator of these abnormalities, and may decrease more rapidly than correction of the metabolic abnormalities. As part of overall DKA management, dextrose should be added to IV fluids to prevent hypoglycemia, usually once serum glucose is between 250 to 300 mg/dL but it may be required sooner if serum glucose has decreased precipitously. Generally, only dextrose 5% is necessary and is added to NS or <sup>1</sup>/<sub>2</sub>NS; however, dextrose 10% or 12.5% may be necessary in some cases (ADA [Wolfsdorf 2006]; ISPAD [Wolfsdorf 2014]). Refer to institution-specific protocols where appropriate.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Continuous IV infusion:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Initial:</i> 0.05 to 0.1 units/kg/<b>hour</b>; continue the rate at 0.05 to 0.1 units/kg/hour if tolerated until resolution of ketoacidosis (pH &gt;7.3; bicarbonate &gt;15 mEq/L and/or closure of anion gap); <b>Note:</b> Some patients (eg, some young children with DKA, or older children with established diabetes) may have marked sensitivity to insulin requiring lower infusion rates; these lower infusion rates should only be used provided that resolution of the acidosis continues (ADA [Wolfsdorf 2006]; ISPAD [Wolfsdorf 2014]).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>After resolution of DKA:</i> Once ketoacidosis has resolved and oral intake is tolerated, transition to a SubQ insulin regimen. An overlap between discontinuation of IV insulin and administration of SubQ insulin is recommended to ensure adequate plasma insulin levels; timing of SubQ insulin administration prior to infusion discontinuation is dependent on type of insulin used; for SubQ regular insulin: 1 to 2 hours, or for rapid-acting insulin: 15 to 30 minutes (IPSAD [Wolfsdorf 2014]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hyperkalemia:</b> Limited data available: Infants, Children, and Adolescents: IV: 0.1 unit/kg with 400 mg/kg of glucose; usual ratio of combination therapy of insulin to glucose is 1 unit of insulin for every 4 g of glucose (Hegenbarth 2008). An alternate approach is glucose 1 g/kg followed by 0.2 units of insulin/g of glucose administered over 15 to 30 minutes then infused continuously as a similar amount per hour (Fuhrman 2011). In adults, the usual dose is 10 units of insulin mixed with 25 g of dextrose (50 mL of D<sub>50</sub>W) administered over 15 to 30 minutes (ACLS [Vanden Hoek 2010]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hyperosmolar hyperglycemic state (HHS):</b> Limited data available: Children and Adolescents: <b>Note:</b> Only regular IV insulin should be used. Insulin administration should be initiated when serum glucose concentration is no longer declining at a rate &ge;50 mg/dL per hour with fluid administration alone; earlier initiation may be required in patients with severe ketosis and acidosis. Infusion should continue until reversal of mental status changes and hyperosmolality. Serum glucose is not a direct indicator of these abnormalities, and may decrease more rapidly than correction of the metabolic abnormalities. Refer to institution-specific protocols where appropriate.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Continuous IV infusion: Initial: 0.025 to 0.05 units/kg/<b>hour</b>; titrate dose to achieve a decrease in serum glucose concentration at a rate of 50 to 75 mg/dL per hour; higher rates of decline may be required in some patients; however, if rate of decline exceeds 100 mg/dL per hour discontinue infusion (ISPAD [Wolfsdorf 2014]; Zeitler 2011)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2104989\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2104990\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Insulin requirements are reduced due to changes in insulin clearance or metabolism. There are no dosage adjustments provided in the manufacturer's labeling; however, the following adjustments have been recommended (Aronoff 2007):</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">SubQ, IV: Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">CrCl &gt;50 mL/minute: No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">CrCl 10 to 50 mL/minute: Administer at 75% of normal dose and monitor glucose closely.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">CrCl &lt;10 mL/minute: Administer at 50% of normal dose and monitor glucose closely.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hemodialysis: Because of a large molecular weight (6000 daltons), insulin is not significantly removed by hemodialysis; supplemental dose is not necessary</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Peritoneal dialysis: Because of a large molecular weight (6000 daltons), insulin is not significantly removed by peritoneal dialysis; supplemental dose is not necessary</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Continuous renal replacement therapy: Administer 75% of normal dose and monitor glucose closely; supplemental dose is not necessary</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8092960\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling; dosage requirements may be reduced and patients may require more frequent dose adjustment and glucose monitoring.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2104923\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Injection: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">HumuLIN R: 100 units/mL (3 mL, 10 mL) [contains metacresol, phenol]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">NovoLIN R: 100 units/mL (10 mL) [contains metacresol]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">NovoLIN R ReliOn: 100 units/mL (10 mL) [contains metacresol]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Subcutaneous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">HumuLIN R U-500 (CONCENTRATED): 500 units/mL (20 mL) [contains metacresol]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Pen-injector, Subcutaneous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">HumuLIN R U-500 KwikPen: 500 units/mL (3 mL) [contains metacresol]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2104963\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50772805\" class=\"block foccan drugH1Div\"><span class=\"drugH1\">Dosage Forms: Canada</span>\n    <p style=\"text-indent:0em;\">Solution Pen-injector, Subcutaneous: Entuzity KwikPen: 500 units/mL (3 mL) [contains metacresol]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2104992\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">SubQ administration: Do not use if solution is viscous or cloudy; use only if clear and colorless. Regular insulin should be administered approximately 30 minutes before a meal. Cold injections should be avoided. SubQ administration is usually made into the thighs, arms, buttocks, or abdomen; rotate injection sites within the same region to avoid lipodystrophy. Regular insulin is not recommended for use in external SubQ insulin infusion pump.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">U-100 regular insulin: When mixing U-100 regular insulin with other preparations of insulin, regular insulin should be drawn into syringe first.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">U-500 regular insulin (concentrated): Do not dilute or mix U-500 regular insulin. <b>U-500 regular insulin vials are to be used only in conjunction with a dedicated U-500 insulin syringe; dosage conversion is not required with the U-500 syringe.</b> Only in cases where the U-500 insulin syringe is not available, a U-100 insulin syringe or a tuberculin syringe may be necessary. When using a U-100 syringe or a tuberculin syringe to deliver Humulin R U-500 (from vial), a conversion step is required to ensure the correct amount of Humulin R U-500 is drawn up in the syringe. To avoid dosing errors when using a U-100 insulin syringe, the prescribed dose should be written in actual insulin units and as unit markings on the U-100 insulin syringe (eg , Humulin R U-500 50 units = 10 units on a U-100 insulin syringe). To avoid dosing errors when using a tuberculin syringe, the prescribed dose should be written in actual insulin units and as a volume (eg, Humulin R U-500 50 units = 0.1 mL on a tuberculin syringe). Do not perform dose conversions when using the KwikPen; the dose window shows the number of units to be injected. Do not transfer KwikPen insulin into a syringe for administration.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IM administration: <b>Do not administer U-500 regular insulin IM.</b> Do not use if solution is viscous or cloudy; use only if clear and colorless. May be administered IM in selected clinical situations; close monitoring of blood glucose and serum potassium as well as medical supervision is required.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV administration: <b>Do not administer U-500 regular insulin or mixtures of insulin formulations IV. </b>Do not use if solution is viscous or cloudy; use only if clear and colorless. May be administered IV with close monitoring of blood glucose and serum potassium; appropriate medical supervision is required. If possible, avoid IV bolus administration in pediatric patients with DKA; may increase risk of cerebral edema.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV infusions: To minimize insulin adsorption to plastic IV tubing: Insulin loss will occur by adsorption to plastic (ie, PVC, polyethylene, polyolefin, polypropylene) IV containers and tubing (Greenwood 2012; Hirsch 1977; Hirsch 1981; Rocchio 2013; Thompson 2012). Therefore, flush the IV tubing with a priming infusion of 20 mL from the insulin infusion, whenever a new IV tubing set is added to the insulin infusion container (SCCM [Jacobi 2012]; Thompson 2012).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Note:</b> Also refer to institution-specific protocols where appropriate.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">If insulin is required prior to the availability of the insulin drip, regular insulin should be administered by IV push injection.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Because of insulin adsorption to plastic IV tubing or infusion bags, the actual amount of insulin being administered via IV infusion could be substantially less than the apparent amount. Therefore, adjustment of the IV infusion rate should be based on effect and not solely on the apparent insulin dose. The apparent dose may be used as a starting point for determining the subsequent SubQ dosing regimen (Moghissi 2009); however, the transition to SubQ administration requires continuous medical supervision, frequent monitoring of blood glucose, and careful adjustment of therapy. In addition, SubQ insulin should be given 1 to 4 hours prior to the discontinuation of IV insulin to prevent hyperglycemia (Moghissi 2009).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14472660\" class=\"block uica drugH1Div\"><span class=\"drugH1\">Usual Infusion Concentrations: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>IV infusion:</b> 100 units in 100 mL (concentration: 1 unit/mL) of NS</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14472661\" class=\"block uicp drugH1Div\"><span class=\"drugH1\">Usual Infusion Concentrations: Pediatric</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>IV infusion:</b> 0.1 unit/mL, 0.5 unit/mL, <b>or</b> 1 unit/mL</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2105108\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Diabetes mellitus:</b> To improve glycemic control in adult and pediatric patients with diabetes mellitus requiring daily doses of more than 200 units of insulin per day</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25474638\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Cadaveric organ recovery (hormonal resuscitation); Gestational diabetes mellitus; Hyperglycemia during critical illness; Adjunct of parenteral nutrition; Diabetic ketoacidosis (DKA); Hyperkalemia; Hyperosmolar hyperglycemic state (HHS)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2104961\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">HumuLIN R may be confused with HumaLOG, Humira, HumuLIN 70/30, HumuLIN N, NovoLIN 70/30, NovoLIN R, NovoLOG</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">NovoLIN R may be confused with HumuLIN R, NovoLIN 70/30, NovoLIN N, NovoLOG</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Insulin may be confused with influenza virus vaccine. Medication errors have occurred when insulin was inadvertently administered instead of influenza virus vaccine. These products are refrigerated and may be stored in close proximity to each other.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error. <b><i>Due to the number of insulin preparations, it is essential to identify/clarify the type of insulin to be used.</i></b></p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Geriatric Patients: High-Risk Medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Beers Criteria: Insulin (short- or rapid-acting insulin products used for sliding scale) is identified in the Beers Criteria as a potentially inappropriate medication to be avoided in patients 65 years and older (independent of diagnosis or condition) due to higher risk of hypoglycemia associated with sliding scale insulin without improvements in hyperglycemia, regardless of care setting. Recommendation pertains to the sole use of short- or rapid-acting insulins in the absence of basal or long-acting insulin; recommendation does not apply to the titration of basal insulin or the use of additional short- or rapid-acting insulin in conjunction with scheduled insulin (ie, correction insulin) (Beers Criteria [AGS 2015]).</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Administration issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Concentrated solutions (eg, U-500) should not be available in patient care areas. U-500 regular insulin should be stored, dispensed, and administered separately from U-100 regular insulin. U-500 insulin vials are to be used in conjunction only with a dedicated U-500 insulin syringe. Though no longer recommended by the manufacturer, in cases where the U-500 insulin syringe is not available, a U-100 insulin syringe or a tuberculin syringe may be used (conversion step required to ensure correct dose is drawn up). For patients who receive U-500 insulin in the hospital setting, highlighting the strength prominently on the patient&rsquo;s medical chart and medication record may help to reduce dispensing errors. For patients being discharged from the hospital and/or in the outpatient setting, a U-500 insulin syringe is available by prescription only and should be prescribed/dispensed in conjunction with U-500 insulin vials.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Other safety concerns:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Cross-contamination may occur if insulin pens are shared among multiple patients. Steps should be taken to prohibit sharing of insulin pens.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2104969\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Frequency not always defined.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Peripheral edema</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Dermatologic: Erythema at injection site, injection site pruritus</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Endocrine &amp; metabolic: Hypoglycemia, hypokalemia, weight gain</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hypersensitivity: Anaphylaxis, hypersensitivity, hypersensitivity reaction</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Local: Hypertrophy at injection site, lipoatrophy at injection site</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2104968\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to regular insulin or any component of the formulation; during episodes of hypoglycemia.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Documentation of allergenic cross-reactivity for insulin is limited. However, because of similarities in chemical structure and/or pharmacologic actions, the possibility of cross-sensitivity cannot be ruled out with certainty.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2105113\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity: Severe, life-threatening, generalized allergic reactions, including anaphylaxis, may occur. If hypersensitivity reactions occur, discontinue therapy, treat the patient with supportive care and monitor until signs and symptoms resolve.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypoglycemia: The most common adverse effect of insulin is hypoglycemia. The timing of hypoglycemia differs among various insulin formulations. Hypoglycemia may result from changes in meal pattern (eg, macronutrient content, timing of meals), changes in the level of physical activity, increased work or exercise without eating, or changes to coadministered medications. Use of long-acting insulin preparations (eg, insulin degludec, insulin detemir, insulin glargine) may delay recovery from hypoglycemia. Patients with renal or hepatic impairment may be at a higher risk. Symptoms differ in patients and may change over time in the same patient; awareness may be less pronounced in those with long standing diabetes, diabetic nerve disease, patients taking beta-blockers, or in those who experience recurrent hypoglycemia. Profound and prolonged episodes of hypoglycemia may result in convulsions, unconsciousness, temporary or permanent brain damage, or even death. Insulin requirements may be altered during illness, emotional disturbances, or other stressors. Instruct patients to use caution with ethanol; may increase risk of hypoglycemia.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypokalemia: Insulin (especially IV insulin) causes a shift of potassium from the extracellular space to the intracellular space, possibly producing hypokalemia. If left untreated, hypokalemia may result in respiratory paralysis, ventricular arrhythmia and even death. Use with caution in patients at risk for hypokalemia (eg, loop diuretic use). Monitor serum potassium frequently with IV insulin use and supplement potassium when necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiac disease: Concurrent use with peroxisome proliferator-activated receptor (PPAR)-gamma agonists, including thiazolidinediones (TZDs) may cause dose-related fluid retention and lead to or exacerbate heart failure, particularly when used in combination with insulin. If PPAR-gamma agonists are prescribed, monitor for signs and symptoms of heart failure. If heart failure develops, consider PPAR-gamma agonist dosage reduction or therapy discontinuation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use with caution in patients with hepatic impairment; increased risk of hypoglycemia. Dosage requirements may be reduced and patients may require more frequent dose adjustment and glucose monitoring.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with renal impairment; increased risk of hypoglycemia. Dosage requirements may be reduced and patients may require more frequent dose adjustment and glucose monitoring.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues: </i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hospitalized patients with diabetes: Exclusive use of a sliding scale insulin regimen in the inpatient hospital setting is strongly discouraged. In the critical care setting, continuous IV insulin infusion has been shown to best achieve glycemic targets. In noncritically ill patients with either poor oral intake or taking nothing by mouth, <b>basal</b> insulin or <b>basal</b> plus bolus is preferred. In noncritically ill patients with adequate nutritional intake, a combination of <b>basal </b>insulin, nutritional, and correction components is preferred. An effective insulin regimen will achieve the goal glucose range without the risk of severe hypoglycemia. A blood glucose value &lt;70 mg/dL should prompt a treatment regimen review and change, if necessary, to prevent further hypoglycemia (ADA 2017d).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Multiple-dose injection pens: According to the Centers for Disease Control and Prevention (CDC), pen-shaped injection devices should never be used for more than one person (even when the needle is changed) because of the risk of infection. The injection device should be clearly labeled with individual patient information to ensure that the correct pen is used (CDC 2012).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Product variation: Human insulin differs from animal-source insulin. Any change of insulin should be made cautiously; changing manufacturers, type, and/or method of manufacture may result in the need for a change of dosage.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; U-500 regular insulin: <b>U-500 regular insulin is a concentrated insulin formulation which contains 500 units of insulin per mL and is intended for subQ administration only;</b> <b>do not administer IV or IM or use in an insulin pump</b>. Prescribe only to patients who require more than 200 units of insulin per day. Doses from a U-500 regular insulin vial should be drawn up only with a dedicated U-500 insulin syringe. Do not mix or dilute U-500 regular insulin with other insulin formulations. Insulin U-500 also has a delayed onset and longer duration of action compared to regular insulin U-100, and has both prandial and basal properties (ADA 2017f). Do not perform dose conversions when using the KwikPen, the dose window shows the number of units to be injected. Do not transfer insulin from the KwikPen to a syringe for administration.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Diabetes mellitus: The general objective of exogenous insulin therapy is to approximate the physiologic pattern of insulin secretion which is characterized by two distinct phases. Phase 1 insulin secretion suppresses hepatic glucose production and phase 2 insulin secretion occurs in response to carbohydrate ingestion; therefore, exogenous insulin therapy may consist of basal insulin (eg, intermediate- or long-acting insulin via continuous subcutaneous insulin infusion [CSII]) and/or preprandial insulin (eg, short- or rapid-acting insulin) (see Related Information: Insulin Products). Patients with type 1 diabetes do not produce endogenous insulin; therefore, these patients require both basal and preprandial insulin administration. Patients with type 2 diabetes retain some beta-cell function in the early stages of their disease; however, as the disease progresses, phase 1 insulin secretion may become completely impaired and phase 2 insulin secretion becomes delayed and/or inadequate in response to meals. Therefore, patients with type 2 diabetes may be treated with oral antidiabetic agents, basal insulin, and/or preprandial insulin depending on the stage of disease and current glycemic control. Since treatment regimens often consist of multiple agents, dosage adjustments must address the specific phase of insulin release that is primarily contributing to the patient&rsquo;s impaired glycemic control. Treatment and monitoring regimens must be individualized.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; IM administration: Regular insulin U-100 (ie, 100 units/mL) may be administered IM in selected clinical situations to control hyperglycemia (eg, DKA); close monitoring of blood glucose and serum potassium as well as medical supervision is required. Do not administer U-500 regular insulin IM.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; IV administration: Regular insulin U-100 (ie, 100 units/mL) may be administered IV in selected clinical situations (eg, DKA, hyperkalemia); close monitoring of blood glucose and serum potassium as well as medical supervision is required. Do not administer U-500 regular insulin IV.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Patient education: Diabetes self-management education (DSME) is essential to maximize the effectiveness of therapy.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2104975\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2104974\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9030&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Alpha-Lipoic Acid: May enhance the hypoglycemic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Androgens: May enhance the hypoglycemic effect of Blood Glucose Lowering Agents.<b> Exceptions: </b>Danazol.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antidiabetic Agents: May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Beta-Blockers: May enhance the hypoglycemic effect of Insulins.<b> Exceptions: </b>Levobunolol; Metipranolol.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dipeptidyl Peptidase-IV Inhibitors: May enhance the hypoglycemic effect of Insulins. Management: Consider a decrease in insulin dose when initiating therapy with a dipeptidyl peptidase-IV inhibitor and monitor patients for hypoglycemia.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Edetate CALCIUM Disodium: May enhance the hypoglycemic effect of Insulins.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Edetate Disodium: May enhance the hypoglycemic effect of Insulins.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Glucagon-Like Peptide-1 Agonists: May enhance the hypoglycemic effect of Insulins. Management: Consider insulin dose reductions when used in combination with glucagon-like peptide-1 agonists. Avoid the use of lixisenatide in patients receiving  both basal insulin and a sulfonylurea.<b> Exceptions: </b>Liraglutide.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Guanethidine: May enhance the hypoglycemic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Herbs (Hypoglycemic Properties): May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hyperglycemia-Associated Agents: May diminish the therapeutic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypoglycemia-Associated Agents: May enhance the hypoglycemic effect of other Hypoglycemia-Associated Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypoglycemia-Associated Agents: Antidiabetic Agents may enhance the hypoglycemic effect of Hypoglycemia-Associated Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Liraglutide: May enhance the hypoglycemic effect of Insulins. Management: If liraglutide is used for the treatment of diabetes (Victoza), consider insulin dose reductions. The combination of liraglutide and insulin should be avoided if liraglutide is used exclusively for weight loss (Saxenda).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Macimorelin: Insulins may diminish the diagnostic effect of Macimorelin. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metreleptin: May enhance the hypoglycemic effect of Insulins. Management: Insulin dosage adjustments (including potentially large decreases) may be required to minimize the risk for hypoglycemia with concurrent use of metreleptin.  Monitor closely.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Monoamine Oxidase Inhibitors: May enhance the hypoglycemic effect of Blood Glucose Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pegvisomant: May enhance the hypoglycemic effect of Blood Glucose Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pioglitazone: May enhance the adverse/toxic effect of Insulins. Specifically, the risk for hypoglycemia, fluid retention, and heart failure may be increased with this combination. Management: If insulin is combined with pioglitazone, dose reductions should be considered to reduce the risk of hypoglycemia. Monitor patients for fluid retention and signs/symptoms of heart failure.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pramlintide: May enhance the hypoglycemic effect of Insulins. Management: Upon initiation of pramlintide, decrease mealtime insulin dose by 50% to reduce the risk of hypoglycemia. Monitor blood glucose frequently and individualize further insulin dose adjustments based on glycemic control.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prothionamide: May enhance the hypoglycemic effect of Blood Glucose Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Quinolones: May enhance the hypoglycemic effect of Blood Glucose Lowering Agents. Quinolones may diminish the therapeutic effect of Blood Glucose Lowering Agents. Specifically, if an agent is being used to treat diabetes, loss of blood sugar control may occur with quinolone use.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ritodrine: May diminish the therapeutic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rosiglitazone: Insulins may enhance the adverse/toxic effect of Rosiglitazone. Specifically, the risk of fluid retention, heart failure, and hypoglycemia may be increased with this combination. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Salicylates: May enhance the hypoglycemic effect of Blood Glucose Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Selective Serotonin Reuptake Inhibitors: May enhance the hypoglycemic effect of Blood Glucose Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium-Glucose Cotransporter 2 (SLGT2) Inhibitors: May enhance the hypoglycemic effect of Insulins. Management: Consider a decrease in insulin dose when initiating therapy with a sodium-glucose cotransporter 2 inhibitor and monitor patients for hypoglycemia.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thiazide and Thiazide-Like Diuretics: May diminish the therapeutic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14079518\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">B (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2105111\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;\">Animal reproduction studies have not been conducted. Exogenous insulin bound to anti-insulin antibodies can be detected in cord blood (Menon 1990).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">In women with diabetes, maternal hyperglycemia can be associated with congenital malformations as well as adverse effects in the fetus, neonate, and the mother (ACOG 2005; ADA 2018c; Metzger 2007). To prevent adverse outcomes, prior to conception and throughout pregnancy, maternal blood glucose and HbA<sub>1c</sub> should be kept as close to target goals as possible but without causing significant hypoglycemia (ADA 2018c; Blumer 2013; Lambert 2013).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Insulin requirements tend to fall during the first trimester of pregnancy and increase in the later trimesters, peaking at 28 to 32 weeks' gestation. Following delivery, insulin requirements decrease rapidly (ACOG 2005).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Insulin therapy is the preferred treatment of type 1 and type 2 diabetes in pregnant women, as well as GDM when pharmacologic therapy is needed (ACOG 190 2018; ADA 2018c). Rapid acting insulins may be preferred over regular human insulin in women trying to conceive (Blumer 2013); however, there is no need to switch a pregnant woman who is well-controlled on injectable human insulin to a short acting analogue (Lambert 2013). Regular insulin is used intravenously for glycemic control during labor.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2104967\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Both exogenous and endogenous insulin are present in breast milk (study not conducted with this preparation) (Whitmore 2012). Breastfeeding is encouraged for all women, including those with type 1, type 2, or GDM (ACOG 2005; ADA 2018c; Blumer 2013; Metzger 2007). A small snack (such as milk) before breastfeeding may help decrease the risk of hypoglycemia in women with pregestational diabetes (ACOG 2005; Reader 2004).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Adverse events have not been reported in breastfeeding infants following use of regular insulin for injection. Regular insulin is compatible with breastfeeding; however, adjustments of the mothers' insulin dose may be needed.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2104991\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Individualized medical nutrition therapy (MNT) based on ADA recommendations is an integral part of therapy.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2104996\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Critically ill patients receiving insulin infusion: Blood glucose every 1 to 2 hours. <b>Note:</b> Every 4 hour blood glucose monitoring is not recommended unless a low hypoglycemia rate is demonstrated with the insulin protocol used. Arterial or venous whole blood sampling is recommended for patients in shock, on vasopressor therapy, or with severe edema, and when on a prolonged insulin infusion (SCCM [Jacobi 2012]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Diabetes mellitus: Plasma glucose, electrolytes, HbA<sub>1c</sub> (at least twice yearly in patients who have stable glycemic control and are meeting treatment goals; quarterly in patients not meeting treatment goals or with therapy change [ADA 2017a]); renal function, hepatic function, weight</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">DKA/HHS: Serum electrolytes, glucose, BUN, creatinine, osmolality, venous pH (repeat arterial blood gases are generally unnecessary), anion gap, urine output, urinalysis, mental status</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hyperkalemia: Serum potassium and glucose must be closely monitored to avoid hypokalemia, rebound hyperkalemia, and hypoglycemia.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2105121\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Recommendations for glycemic control in nonpregnant adults with diabetes (ADA 2017c):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">HbA<sub>1c</sub>: &lt;7% (a more aggressive [&lt;6.5%] or less aggressive [&lt;8%] HbA1c goal may be targeted based on patient-specific characteristics)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Preprandial capillary blood glucose: 80 to 130 mg/dL</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Peak postprandial capillary blood glucose: &lt;180 mg/dL</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Recommendations for glycemic control in older adults (&ge;65 years) with diabetes (ADA 2017b):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">HbA<sub>1c</sub>: &lt;7.5% (healthy); &lt;8% (complex/intermediate health); &lt;8.5% (very complex/poor health) (individualization may be appropriate based on patient and caregiver preferences)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Preprandial capillary blood glucose: 90 to 130 mg/dL (healthy); 90 to 150 mg/dL (complex/intermediate health); 100 to 180 mg/dL (very complex/poor health)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Bedtime capillary blood glucose: 90 to 150 mg/dL (healthy); 100 to 180 mg/dL (complex/intermediate health); 110 to 200 mg/dL (very complex/poor health)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Recommendations for glycemic control in pediatric (all age groups) patients with type 1 diabetes (ADA 2017e):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">HbA<sub>1c</sub>: &lt;7.5% (individualization may be appropriate based on patient-specific characteristics; &lt;7% is reasonable if it can be achieved without excessive hypoglycemia)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Preprandial capillary blood glucose: 90 to 130 mg/dL</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Bedtime and overnight capillary blood glucose: 90 to 150 mg/dL</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Recommendations for hospitalized adult patients with diabetes (ADA 2017d): Target glucose range: 140 to 180 mg/dL (majority of critically ill and noncritically ill patients; &lt;140 mg/dL may be appropriate for selected patients, if it can be achieved without excessive hypoglycemia). Initiate insulin therapy for persistent hyperglycemia at &ge;180 mg/dL</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Recommendations for perioperative care in adult patients with diabetes (ADA 2017d): Target glucose range during perioperative period: Consider targeting 80 to 180 mg/dL</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2104981\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Insulin acts via specific membrane-bound receptors on target tissues to regulate metabolism of carbohydrate, protein, and fats. Target organs for insulin include the liver, skeletal muscle, and adipose tissue.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Within the liver, insulin stimulates hepatic glycogen synthesis. Insulin promotes hepatic synthesis of fatty acids, which are released into the circulation as lipoproteins. Skeletal muscle effects of insulin include increased protein synthesis and increased glycogen synthesis. Within adipose tissue, insulin stimulates the processing of circulating lipoproteins to provide free fatty acids, facilitating triglyceride synthesis and storage by adipocytes; also directly inhibits the hydrolysis of triglycerides. In addition, insulin stimulates the cellular uptake of amino acids and increases cellular permeability to several ions, including potassium, magnesium, and phosphate. By activating sodium-potassium ATPases, insulin promotes the intracellular movement of potassium.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Normally secreted by the pancreas, insulin products are manufactured for pharmacologic use through recombinant DNA technology using either <i>E. coli</i> or <i>Saccharomyces cerevisiae</i>. Regular insulin has an identical structure to that of native human insulin. Insulins are categorized based on the onset, peak, and duration of effect (eg, rapid-, short-, intermediate-, and long-acting insulin). Insulin regular is a short-acting insulin analog.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2104982\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Onset and duration of hypoglycemic effects depend upon the route of administration (absorption and onset of action are more rapid after deeper IM injections than after SubQ), site of injection (onset and duration are progressively slower with SubQ injection into the abdomen, arm, buttock, or thigh respectively), volume and concentration of injection, and the preparation administered. Rate of absorption, onset, and duration of activity may be affected by exercise, presence of lipodystrophy, local blood supply, and/or temperature.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">Onset of action: SubQ: 0.25 to 0.5 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Peak effect: SubQ: U-100: 2.5 to 5 hours; U-500: 4 to 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Duration: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV: U-100: 2 to 6 hours </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">SubQ: U-100: 4 to 12 hours (may increase with dose); U-500: 13 to 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: IV, SubQ: V<sub>d</sub>: 0.26 to 0.36 L/kg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bioavailability: SubQ: 55% to 77%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: IV: ~0.5 to 1 hour (dose-dependent); SubQ: 1.5 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak, plasma: SubQ: 0.8 to 2 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3422171\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (HumuLIN R Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 units/mL (3 mL): $53.53</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (HumuLIN R U-500 (CONCENTRATED) Subcutaneous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 units/mL (20 mL): $1,784.40</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (NovoLIN R Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 units/mL (10 mL): $165.24</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (NovoLIN R ReliOn Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 units/mL (10 mL): $165.24</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution Pen-injector</b> (HumuLIN R U-500 KwikPen Subcutaneous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 units/mL (3 mL): $344.52</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6038885\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Actrapid (DK, SG);</li>\n      <li>Glinux-R (MX);</li>\n      <li>Huminsulin Basal (CH);</li>\n      <li>Huminsulin Normal (AT);</li>\n      <li>Humulin (UA);</li>\n      <li>Humulin R (AE, AU, BB, BG, BH, BM, BZ, CL, CN, CO, CR, CY, CZ, DO, EE, EG, GT, GY, HK, HR, HU, ID, IL, IT, JO, KR, KW, LB, LI, LK, LT, LU, MX, MY, NI, NZ, PA, PE, PH, PK, PY, QA, RO, SA, SE, SI, SK, SR, SV, TH, TR, VN);</li>\n      <li>Humulin Regular (DK, FI, GR, PT, RU);</li>\n      <li>Humulin S (GB);</li>\n      <li>Humulina Regular (ES);</li>\n      <li>Humuline R (BE);</li>\n      <li>Iletin-R (IN);</li>\n      <li>Insolidd-R (ZW);</li>\n      <li>Insugen R (MY, TH);</li>\n      <li>Insugen-R (ZW);</li>\n      <li>Insuget R (PH);</li>\n      <li>Insulet R (BD);</li>\n      <li>Insulin Insulatard HM (CH);</li>\n      <li>Insulina Humulin R (AR);</li>\n      <li>Insuman (NO);</li>\n      <li>Insuman Basal (ET, IE, TZ, ZW);</li>\n      <li>Insuman R (CL);</li>\n      <li>Insuman Rapid (TH, ZW);</li>\n      <li>Jusline R (TZ);</li>\n      <li>Scilin R (PH);</li>\n      <li>Umuline Rapide (FR);</li>\n      <li>Winsulin-R (TH);</li>\n      <li>Wosulin R (BR, TZ)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    American College of Obstetricians and Gynecologists (ACOG) Committee on Practice Bulletins, &quot;Clinical Management Guidelines for Obstetrician-Gynecologists. Number 60, March 2005. Pregestational Diabetes Mellitus,&quot; <i>Obstet Gynecol</i>, 2005, 105(3):675-85.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/insulin-regular-drug-information/abstract-text/15738045/pubmed\" target=\"_blank\" id=\"15738045\">15738045</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American College of Obstetricians and Gynecologists (ACOG)Committee on Practice Bulletins&mdash;Obstetrics. ACOG Practice Bulletin No. 190: Gestational Diabetes Mellitus. <i>Obstet Gynecol</i>. 2018;131(2):e49-e64.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/insulin-regular-drug-information/abstract-text/29370047/pubmed\" target=\"_blank\" id=\"29370047\">29370047</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"27979893\"></a>American Diabetes Association (ADA). 6. Glycemic targets. <i>Diabetes Care</i>. 2017a;40(suppl 1):S48&ndash;S56.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/insulin-regular-drug-information/abstract-text/27979893/pubmed\" target=\"_blank\" id=\"27979893\">27979893</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Diabetes Association (ADA). 11. Older adults. <i>Diabetes Care</i>. 2017b;40(suppl 1):S99&ndash;S104.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/insulin-regular-drug-information/abstract-text/27979898/pubmed\" target=\"_blank\" id=\"27979898\">27979898</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Diabetes Association (ADA). 13. Management of Diabetes in Pregnancy: Standards of Medical Care in Diabetes-2018. <i>Diabetes Care</i>. 2018c;41(Suppl 1):S137-S143.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/insulin-regular-drug-information/abstract-text/29222384/pubmed\" target=\"_blank\" id=\"29222384\">29222384</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Diabetes Association (ADA). 14. Diabetes care in the hospital. <i>Diabetes Care</i>. 2017d;40(suppl 1):S120&ndash;S127.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/insulin-regular-drug-information/abstract-text/27979901/pubmed\" target=\"_blank\" id=\"27979901\">27979901</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Diabetes Association (ADA). 12. Children and adolescents. <i>Diabetes Care</i>. 2017e;40(suppl 1):S105&ndash;S113.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/insulin-regular-drug-information/abstract-text/27979899/pubmed\" target=\"_blank\" id=\"27979899\">27979899</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Diabetes Association (ADA). 8. Pharmacologic approaches to glycemic treatment. <i>Diabetes Care.</i> 2017f;40(suppl 1):S64&ndash;S74.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/insulin-regular-drug-information/abstract-text/27979895/pubmed\" target=\"_blank\" id=\"27979895\">27979895</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Diabetes Association; American Psychiatric Association; American Association of Clinical Endocrinologists; North American Association for the Study of Obesity, &ldquo;Consensus Development Conference on Antipsychotic Drugs and Obesity and Diabetes,&rdquo; <i>Diabetes Care</i>, 2004, 27(2):596-601.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/insulin-regular-drug-information/abstract-text/14747245/pubmed\" target=\"_blank\" id=\"14747245\">14747245</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Geriatrics Society 2015 Beers Criteria Update Expert Panel. American Geriatrics Society 2015 updated Beers Criteria for potentially inappropriate medication use in older adults. <i>J Am Geriatr Soc</i>. 2015;63(11):2227-2246. doi:10.1111/jgs.13702.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/insulin-regular-drug-information/abstract-text/26446832/pubmed\" target=\"_blank\" id=\"26446832\">26446832</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aronoff GR, Bennett WM, Berns JS, et al, eds. <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>. 5th ed. Philadelphia, PA: American College of Physicians; 2007.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Blumer I, Hadar E, Hadden DR, et al. Diabetes and pregnancy: an endocrine society clinical practice guideline. <i>J Clin Endocrinol Metab</i>. 2013;98(11):4227-4249.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/insulin-regular-drug-information/abstract-text/24194617 /pubmed\" target=\"_blank\" id=\"24194617 \">24194617 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Brown G and Dodek P, &ldquo;Intravenous Insulin Nomogram Improves Blood Glucose Control in the Critically Ill,&rdquo; <i>Crit Care Med</i>, 2001, 29(9):1714-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/insulin-regular-drug-information/abstract-text/11546970/pubmed\" target=\"_blank\" id=\"11546970\">11546970</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Brunkhorst FM, Engel C, Bloos F, et al, &ldquo;Intensive Insulin Therapy and Pentastarch Resuscitation in Severe Sepsis,&rdquo; <i>N Engl J Med</i>, 2008, 358(2):125-39.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/insulin-regular-drug-information/abstract-text/18184958/pubmed\" target=\"_blank\" id=\"18184958\">18184958</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Canadian Diabetes Association Clinical Practice Guidelines Expert Committee, &quot;Canadian Diabetes Association 2013 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada,&quot; <i>Can J Diabetes</i>, 2013, 35(Suppl 1):1-212.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention (CDC). CDC clinical reminder: insulin pens must never be used for more than one person. Centers for Disease Control and Prevention website. <a href=\"http://www.cdc.gov/injectionsafety/clinical-reminders/insulin-pens.html\" target=\"_blank\">http://www.cdc.gov/injectionsafety/clinical-reminders/insulin-pens.html</a>. Updated January 5, 2012. Accessed March 18, 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Copeland KC, Silverstein J, Moore KR, Prazar GE, Raymer T, et al; American Academy of Pediatrics. Management of newly diagnosed type 2 diabetes mellitus (T2DM) in children and adolescents. <i>Pediatrics</i>. 2013;131(2):364-382. doi: 10.1542/peds.2012-3494.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/insulin-regular-drug-information/abstract-text/23359574/pubmed\" target=\"_blank\" id=\"23359574\">23359574</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dailey G, &ldquo;New Strategies for Basal Insulin Treatment in Type 2 Diabetes Mellitus,&rdquo; <i>Clin Ther</i>, 2004, 26(6):889-901.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Danne T, Bangstad HJ, Deeb L, Jarosz-Chobot P, Mungaie L, et al; International Society for Pediatric and Adolescent Diabetesl. ISPAD Clinical Practice Consensus Guidelines 2014. Insulin treatment in children and adolescents with diabetes. <i>Pediatr Diabetes</i>. 2014;15 (suppl 20):115-134. doi: 10.1111/pedi.12184.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/insulin-regular-drug-information/abstract-text/25182312/pubmed\" target=\"_blank\" id=\"25182312\">25182312</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Davies M, Storms F, Shutler S, et al, &ldquo;Improvement of Glycemic Control in Subjects With Poorly Controlled Type 2 Diabetes,&rdquo; <i>Diabetes Care</i>, 2005, 28(6):1282-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/insulin-regular-drug-information/abstract-text/15920040/pubmed\" target=\"_blank\" id=\"15920040\">15920040</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Deedwania P, Kosiborod M, Barrett E, et al, &ldquo;Hyperglycemia and Acute Coronary Syndrome: A Scientific Statement from the American Heart Association Diabetes Committee of the Council on Nutrition, Physical Activity, and Metabolism,&rdquo; <i>Circulation</i>, 2008, 117(12):1610-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/insulin-regular-drug-information/abstract-text/18299505/pubmed\" target=\"_blank\" id=\"18299505\">18299505</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Field JM, Hazinski MF, Sayre MR, et al, &ldquo;Part 1: Executive Summary: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care,&rdquo; <i>Circulation</i>, 2010, 122 (18 Suppl 3):640-56.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/insulin-regular-drug-information/abstract-text/20956217/pubmed\" target=\"_blank\" id=\"20956217\">20956217</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fuhrman B, Zimmerman J, eds. <i>Pediatric Critical Care</i>. 4th ed. Elsevier Health; 2011.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gerstein HC, Yale JF, Harrist SB, et al, &ldquo;A Randomized Trial of Adding Insulin Glargine Vs. Avoidance of Insulin in People with Type 2 Diabetes on Either No Oral Glucose-Lowering Agents or Submaximal Doses of Metformin and/or Sulphonylureas: The Canadian INSIGHT (Implementing New Strategies with Insulin Glargine for Hyperglycaemia Treatment) Study,&rdquo; <i>Diabet Med</i>, 2006, 23(7):736-42.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/insulin-regular-drug-information/abstract-text/16842477/pubmed\" target=\"_blank\" id=\"16842477\">16842477</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Greenwood BC, Chesnick MA, Szumita PM, Belisle C, Cotugno M. Stability of regular human insulin extemporaneously prepared in 0.9% sodium chloride in a polyvinyl chloride bag. <i>Hosp Pharm</i>. 2012;47(5):367-370.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Handelsman Y, Mechanick JI, Blonde L, et al, &ldquo;American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for Developing a Diabetes Mellitus Comprehensive Care Plan,&rdquo; <i>Endocr Pract</i>, 2011, 17(Suppl 2):1-53.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/insulin-regular-drug-information/abstract-text/21474420/pubmed\" target=\"_blank\" id=\"21474420\">21474420</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hegenbarth MA and American Academy of Pediatrics Committee on Drugs, &ldquo;Preparing for Pediatric Emergencies: Drugs to Consider,&rdquo; <i>Pediatrics,</i> 2008, 121(2):433-43.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/insulin-regular-drug-information/abstract-text/18245435/pubmed\" target=\"_blank\" id=\"18245435\">18245435</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hillis LD, Smith PK, Anderson JL, et al, &ldquo;2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,&rdquo; <i>Circulation</i>, 2011, 124(23):2610-42.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/insulin-regular-drug-information/abstract-text/22064600/pubmed\" target=\"_blank\" id=\"22064600\">22064600</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hirsch JI, Fratkin MJ, Wood JH, Thomas RB. Clinical significance of insulin adsorption by polyvinyl chloride infusion systems. <i>Am J Hosp Pharm</i>. 1977;34(6):583-588.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/insulin-regular-drug-information/abstract-text/406784/pubmed\" target=\"_blank\" id=\"406784\">406784</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hirsch JI, Wood JH, Thomas RB. Insulin adsorption to polyolefin infusion bottles and polyvinyl chloride administration sets. <i>Am J Hosp Pharm</i>. 1981;38(7):995-997.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/insulin-regular-drug-information/abstract-text/7020415/pubmed\" target=\"_blank\" id=\"7020415\">7020415</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Holman RR and Turner RC, &ldquo;Insulin Therapy in Type II Diabetes,&rdquo; <i>Diabetes Res Clin Pract</i>, 1995, (28 Suppl):179-84.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hopkins DF, Cotton SJ, and Williams G, &ldquo;Effective Treatment of Insulin-Induced Edema Using Ephedrine,&rdquo; <i>Diabetes Care</i>, 1993, 16(7):1026-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/insulin-regular-drug-information/abstract-text/8359096/pubmed\" target=\"_blank\" id=\"8359096\">8359096</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Humulin R (insulin regular) [prescribing information]. Indianapolis, IN: Eli Lilly and Company; February 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Humulin R, Humulin N, and Humulin 30/70 (insulin isophane, human biosynthetic [rDNA origin]) [product monograph]. Toronto, Ontario, Canada: Eli Lilly Canada Inc; May 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Humulin R U-500 (insulin regular concentrate) [prescribing information]. Indianapolis, IN: Eli Lilly and Company; October 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Institute for Safe Medication Practice (ISMP) and Vermont Oxford Network, &ldquo;Standard Concentrations of Neonatal Drug Infusions,&rdquo; 2011. Available at https://www.ismp.org/Tools/PediatricConcentrations.pdf</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    International Diabetes Federation, International Society for Pediatric and Adolescent Diabetes. Global IDF/ISPAD guideline for diabetes in childhood and adolescence. 2011. http://www.idf.org/e-library/guidelines/80-the-global-idf-ispad-guidelines-for-diabetes-in-childhood-and-adolescence.html. Accessed: October 21, 2013.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jacobi J, Bircher N, Krinsley J, et al, &ldquo;Guidelines for the Use of an Insulin Infusion for the Management of Hyperglycemia in Critically Ill Patients,&rdquo; <i>Crit Care Med</i>, 2012, 40(12):3251-76.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/insulin-regular-drug-information/abstract-text/23164767/pubmed\" target=\"_blank\" id=\"23164767\">23164767</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Joint Commission on Accreditation of Healthcare Organizations, &ldquo;2005 National Patient Safety Goals.&rdquo; Available at http://www.jointcommission.org/PatientSafety/NationalPatientSafetyGoals/05_npsgs.htm</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kirkman M, Briscoe VJ, Clark N, et al, &quot;Diabetes in Older Adults: A Consensus Report,&quot; <i>J Am Geriatr Soc</i>, 2012; doi: 10.1111/jgs.12035.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/insulin-regular-drug-information/abstract-text/23106132/pubmed\" target=\"_blank\" id=\"23106132\">23106132</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kitabchi AE, Umpierrez GE, Miles JM, et al, &ldquo;Hyperglycemic Crises in Adult Patients With Diabetes,&rdquo; <i>Diabetes Care</i>, 2009, 32(7):1335-43.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/insulin-regular-drug-information/abstract-text/19564476/pubmed\" target=\"_blank\" id=\"19564476\">19564476</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kitabchi AE, Umpierrez GE, Murphy MB, et al, &quot;Hyperglycemic Crises in Diabetes,&rdquo; <i>Diabetes Care</i>, 2004, 27(Suppl 1): 94-102.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/insulin-regular-drug-information/abstract-text/14693938/pubmed\" target=\"_blank\" id=\"14693938\">14693938</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lambert K, Holt RI. The use of insulin analogues in pregnancy.<i> Diabetes Obes Metab</i>. 2013;15(10):888-900.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/insulin-regular-drug-information/abstract-text/23489521 /pubmed\" target=\"_blank\" id=\"23489521 \">23489521 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lazar HL, Philippides G, Fitzgerald C, et al, &ldquo;Glucose-Insulin-Potassium Solutions Enhance Recovery After Urgent Coronary Artery Bypass Grafting,&rdquo; <i>J Thorac Cardiovasc Surg</i>, 1997, 113(2):354-60.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/insulin-regular-drug-information/abstract-text/9040630/pubmed\" target=\"_blank\" id=\"9040630\">9040630</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Malhotra A, &ldquo;Intensive Insulin in Intensive Care,&rdquo; <i> N Engl J Med</i>, 2006, 354(5):516-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/insulin-regular-drug-information/abstract-text/16452564/pubmed\" target=\"_blank\" id=\"16452564\">16452564</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Malmberg K, &ldquo;Prospective Randomised Study of Intensive Insulin Treatment on Long Term Survival After Acute Myocardial Infarction in Patients With Diabetes Mellitus. DIGAMI (Diabetes Mellitus, Insulin Glucose Infusion in Acute Myocardial Infarction) Study Group,&rdquo; <i>BMJ</i>, 1997, 314(7093):1512-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/insulin-regular-drug-information/abstract-text/9169397/pubmed\" target=\"_blank\" id=\"9169397\">9169397</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Meneghini L, Koenen C, Rojas P, et al, &ldquo;Efficacy and Safety of Insulin Detemir in a Large Cohort of Patients With Type 2 Diabetes Using a Simplified Self-Adjusted Dosing Guideline -- Results of the Predictive 303 Study,&rdquo; Presented at: 67th Scientific Sessions of the American Diabetes Association; June 22-25, 2007; Chicago, Ill.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Menon RK, Cohen RM, Sperling MA, et al, &quot;Transplacental Passage of Insulin in Pregnant Women With Insulin-Dependent Diabetes Mellitus. Its Role in Fetal Macrosomia,&quot; <i>N Engl J Med</i>, 1990, 323(5):309-15.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/insulin-regular-drug-information/abstract-text/2195347/pubmed\" target=\"_blank\" id=\"2195347\">2195347</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Metzger BE, Buchanan TA, Coustan DR, et al, &quot;Summary and Recommendations of the Fifth International Workshop-Conference on Gestational Diabetes Mellitus,&quot; <i>Diabetes Care</i>, 2007, 30(Suppl 2):251-60.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/insulin-regular-drug-information/abstract-text/17596481/pubmed\" target=\"_blank\" id=\"17596481\">17596481</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Moghissi ES, Korytkowski MT, DiNardo M, et al, &ldquo;American Association of Clinical Endocrinologists and American Diabetes Association Consensus Statement on Inpatient Glycemic Control,&rdquo; <i>Endocr Pract</i>, 2009, 15(4):353-69.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/insulin-regular-drug-information/abstract-text/19454396/pubmed\" target=\"_blank\" id=\"19454396\">19454396</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Morley JE and Perry HM 3d, &ldquo;The Management of Diabetes Mellitus in Older Individuals,&rdquo; <i>Drugs</i>, 1991, 41(4):548-65.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/insulin-regular-drug-information/abstract-text/1711959/pubmed\" target=\"_blank\" id=\"1711959\">1711959</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mueller-Schoop J, &ldquo;Accidental Intravenous Self-Injection With Insulin Pen,&rdquo; <i>Lancet</i>, 1993, 341(8849):894.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nathan DM, &ldquo;Insulin Treatment in the Elderly Diabetic Patient,&rdquo; <i>Clin Geriatr Med</i>, 1990, 6(4):923-31.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/insulin-regular-drug-information/abstract-text/2224755/pubmed\" target=\"_blank\" id=\"2224755\">2224755</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"19318384\"></a>NICE-SUGAR Study Investigators, Finfer S, Chittock DR, et al, &ldquo;Intensive Versus Conventional Glucose Control in Critically Ill Patients,&rdquo; <i>N Engl J Med</i>, 2009, 360(13):1283-97.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/insulin-regular-drug-information/abstract-text/19318384 /pubmed\" target=\"_blank\" id=\"19318384 \">19318384 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Novolin ge (insulin regular) [product monograph]. Mississauga, Ontario, Canada: Novo Nordisk Canada Inc; March 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Novolin R (insulin regular) [prescribing information]. Princeton, NJ: Novo Nordisk; January 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Oiknine R, Bernbaum M, and Mooradian AD, &ldquo;A Critical Appraisal of the Role of Insulin Analogues in the Management of Diabetes Mellitus,&rdquo; <i>Drugs</i>, 2005, 65(3):325-40.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/insulin-regular-drug-information/abstract-text/15669878/pubmed\" target=\"_blank\" id=\"15669878\">15669878</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Phillips MS, &ldquo;Standardizing I.V. Infusion Concentrations: National Survey Results,&rdquo; <i>Am J Health Syst Pharm</i>, 2011, 68(22):2176-82.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/insulin-regular-drug-information/abstract-text/22058104/pubmed\" target=\"_blank\" id=\"22058104\">22058104</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &ldquo;Proceedings of the American College of Endocrinology Task Force on Inpatient Diabetes and Metabolic Control Consensus Conference, Washington, DC, USA, December 2003,&rdquo; <i>Endocr Pract</i>, 2004, (10 Suppl 2):3-108.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Qaseem A, Humphrey LL, Chou R, et al, &quot;Use of Intensive Insulin Therapy for the Management of Glycemic Control in Hospitalized Patients: A Clinical Practice Guideline From the American College of Physicians,&quot;<i> Ann Intern Med</i>, 2011, 154(4):260-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/insulin-regular-drug-information/abstract-text/21320941/pubmed\" target=\"_blank\" id=\"21320941\">21320941</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Qaseem A, Humphrey LL, Sweet DE, et al,&ldquo;Oral Pharmacologic Treatment of Type 2 Diabetes Mellitus: A Clinical Practice Guideline from the American College of Physicians,&rdquo; <i>Ann Intern Med</i>, 2012, 156(3):218-31.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/insulin-regular-drug-information/abstract-text/22312141/pubmed\" target=\"_blank\" id=\"22312141\">22312141</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Reader D, Franz MJ. Lactation, diabetes, and nutrition recommendations. <i>Curr Diab Rep</i>. 2004;4(5):370-376.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/insulin-regular-drug-information/abstract-text/15461903 /pubmed\" target=\"_blank\" id=\"15461903 \">15461903 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rhodes A, Evans LE, Alhazzani W, et al. Surviving Sepsis Campaign: international guidelines for management of sepsis and septic shock: 2016. <i>Intensive Care Med</i>. 2017;43(3):304-377.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/insulin-regular-drug-information/abstract-text/28101605/pubmed\" target=\"_blank\" id=\"28101605\">28101605</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Riddle MC, Rosenstock J, Gerich J, et al, &ldquo;The Treat-to-Target Trial: Randomized Addition of Glargine or Human NPH Insulin to Oral Therapy of Type 2 Diabetic Patients,&rdquo; <i>Diabetes Care</i>, 2003, 26(11):3080-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/insulin-regular-drug-information/abstract-text/14578243/pubmed\" target=\"_blank\" id=\"14578243\">14578243</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rocchio MA, Belisle CD, Greenwood BC, Cotugno MC, Szumita PM. Evaluation of the maximum beyond-use-date stability of regular human insulin extemporaneously prepared in 0.9% sodium chloride in a polyvinyl chloride bag. <i>Diabetes Metab Syndr Obes</i>. 2013;6:389-392.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/insulin-regular-drug-information/abstract-text/24143117/pubmed\" target=\"_blank\" id=\"24143117\">24143117</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"12605114\"></a>Rosendale JD, Kauffman HM, McBride MA, et al. Aggressive Pharmacologic Donor Management Results in More Transplanted Organs. <i>Transplantation</i>. 2003a;75(4):482-487.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/insulin-regular-drug-information/abstract-text/12605114/pubmed\" target=\"_blank\" id=\"12605114\">12605114</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"12717226\"></a>Rosendale JD, Kauffman HM, McBride MA, et al. Hormonal resuscitation yields more transplanted hearts, with improved early function. <i>Transplantation</i>. 2003b;75(8):1336-1341.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/insulin-regular-drug-information/abstract-text/12717226/pubmed\" target=\"_blank\" id=\"12717226\">12717226</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"12243491\"></a>Rosengard BR, Feng S, Alfrey EJ, et al. Report of the Crystal City meeting to maximize the use of organs recovered from the cadaver donor. <i>Am J Transplant</i>. 2002;2(8):701-711.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/insulin-regular-drug-information/abstract-text/12243491/pubmed\" target=\"_blank\" id=\"12243491\">12243491</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"17488392\"></a>Salim A, Martin M, Brown C, et al. Using thyroid hormone in brain-dead donors to maximize the number of organs available for transplantation.<i>Clin Transplant</i>, 2007;21(3):405-409.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/insulin-regular-drug-information/abstract-text/17488392 /pubmed\" target=\"_blank\" id=\"17488392 \">17488392 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Silverstein J, Klingensmith G, Copeland K, et al, &ldquo;Care of Children and Adolescents With Type 1 Diabetes: A Statement of the American Diabetes Association,&rdquo; <i>Diabetes Care,</i> 2005, 28(1):186-212.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/insulin-regular-drug-information/abstract-text/15616254/pubmed\" target=\"_blank\" id=\"15616254\">15616254</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Simeon PS, Geffner ME, Levin SR, et al, &ldquo;Continuous Insulin Infusions in Neonates: Pharmacologic Availability of Insulin in Intravenous Solutions,&rdquo; <i>J Pediatr</i>, 1994, 124(5 Pt 1):818-20.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/insulin-regular-drug-information/abstract-text/8176576/pubmed\" target=\"_blank\" id=\"8176576\">8176576</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Thompson CD, Vital-Carona J, Faustino EV. The effect of tubing dwell time on insulin adsorption during intravenous insulin infusions. <i>Diabetes Technol Ther</i>.2012;14(10):912-916.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/insulin-regular-drug-information/abstract-text/22746979/pubmed\" target=\"_blank\" id=\"22746979\">22746979</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    van den Berghe G, Wilmer A, Hermans G, et al. Intensive insulin therapy in the medical ICU. <i>N Engl J Med</i>. 2006;354(5):449-461.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/insulin-regular-drug-information/abstract-text/16452557/pubmed\" target=\"_blank\" id=\"16452557\">16452557</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    van den Berghe G, Wouters P, Weekers F, et al. Intensive insulin therapy in the critically ill patients. <i>N Engl J Med</i>. 2001;345(19):1359-1367.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/insulin-regular-drug-information/abstract-text/11794168/pubmed\" target=\"_blank\" id=\"11794168\">11794168</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Vanden Hoek TL, Morrison LJ, Shuster M, et al, &ldquo;Part 12: Cardiac Arrest in Special Situations: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care,&rdquo; <i>Circulation</i>, 2010, 122(18 Suppl 3):829-61.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/insulin-regular-drug-information/abstract-text/20956228/pubmed\" target=\"_blank\" id=\"20956228\">20956228</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Whitmore TJ, Trengove NJ, Graham DF, Hartmann PE. Analysis of insulin in human breast milk in mothers with type 1 and type 2 diabetes mellitus. <i>Int J Endocrinol</i>. 2012;2012:296368.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/insulin-regular-drug-information/abstract-text/22500167 /pubmed\" target=\"_blank\" id=\"22500167 \">22500167 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"18728267\"></a>Wiener RS, Wiener DC, and Larson RJ, &ldquo;Benefits and Risks of Tight Glucose Control in Critically Ill Adults: A Meta-Analysis,&rdquo; <i>JAMA</i>, 2008, 300(8):933-44.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/insulin-regular-drug-information/abstract-text/18728267/pubmed\" target=\"_blank\" id=\"18728267\">18728267</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wolfsdorf J, Craig ME, Daneman D, et al, &ldquo;Diabetic Ketoacidosis,&rdquo; Pediatr Diabetes, 2007, 8(1):28-43. Available at http://onlinelibrary.wiley.com/doi/10.1111/j.1399-5448.2007.00224.x/full17341289</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wolfsdorf J, Glaser N, Sperling MA; American Diabetes Association. Diabetic ketoacidosis in infants, children, and adolescents: A consensus statement from the American Diabetes Association. <i>Diabetes Care</i>. 2006;29(5):1150-1159. doi: 10.2337/diacare.2951150.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/insulin-regular-drug-information/abstract-text/16644656/pubmed\" target=\"_blank\" id=\"16644656\">16644656</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wolfsdorf JI, Allgrove J, Craig ME, Edge J, Glaser N, et al; International Society for Pediatric and Adolescent Diabetes. ISPAD Clinical Practice Consensus Guidelines 2014. Diabetic ketoacidosis and hyperglycemic hyperosmolar state. <i>Pediatr Diabetes</i>. 2014;15 (suppl 20):154-179. doi: 10.1111/pedi.12165.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/insulin-regular-drug-information/abstract-text/25041509/pubmed\" target=\"_blank\" id=\"25041509\">25041509</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"12176957\"></a>Zaroff JG, Rosengard BR, Armstrong WF, et al. Consensus Conference Report: Maximizing Use of Organs Recovered from the Cadaver Donor: Cardiac Recommendations: March 28-29, 2001, Crystal City, Va.<i>Circulation</i>. 2002;106(7):836-841.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/insulin-regular-drug-information/abstract-text/12176957/pubmed\" target=\"_blank\" id=\"12176957\">12176957</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zeitler P, Haqq A, Rosenbloom A, Glaser N; Drugs and Therapeutics Committee of the Lawson Wilkins Pediatric Endocrine Society. Hyperglycemic hyperosmolar syndrome in children: pathophysiological considerations and suggested guidelines for treatment. <i>J Pediatr</i>. 2011;158(1):9-14. doi: 10.1016/j.jpeds.2010.09.048.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/insulin-regular-drug-information/abstract-text/21035820/pubmed\" target=\"_blank\" id=\"21035820\">21035820</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zeitler P, Fu J, Tandon N, Nadeau K, Urakami T, Barrett T, Maahs D; International Society for Pediatric and Adolescent Diabetes. ISPAD Clinical Practice Consensus Guidelines 2014. Type 2 diabetes in the child and adolescent. <i>Pediatr Diabetes</i>. 2014;15 (suppl 20):26-46. doi: 10.1111/pedi.12179.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/insulin-regular-drug-information/abstract-text/25182306/pubmed\" target=\"_blank\" id=\"25182306\">25182306</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9030 Version 194.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Special Alerts\" href=\"#F50707944\" class=\"outlineLink\">Special Alerts</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F2105104\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F2104962\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F2104964\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F2104988\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F2104987\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F2104989\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F2104990\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F8092960\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F2104923\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F2104963\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms: Canada\" href=\"#F50772805\" class=\"outlineLink\">Dosage Forms: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F2104992\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Usual Infusion Concentrations: Adult\" href=\"#F14472660\" class=\"outlineLink\">Usual Infusion Concentrations: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Usual Infusion Concentrations: Pediatric\" href=\"#F14472661\" class=\"outlineLink\">Usual Infusion Concentrations: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F2105108\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25474638\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F2104961\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F2104969\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F2104968\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F2105113\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F2104975\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F2104974\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F14079518\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F2105111\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F2104967\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F2104991\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F2104996\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F2105121\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F2104981\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F2104982\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F3422171\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F6038885\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9030|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=insulin-regular-patient-drug-information\" class=\"drug drug_patient\">Insulin regular: Patient drug information \t</a></li><li><a href=\"topic.htm?path=insulin-regular-pediatric-drug-information\" class=\"drug drug_pediatric\">Insulin regular: Pediatric drug information</a></li></ul></div></div>","javascript":null}